Company Fennec Pharmaceuticals Inc.

Equities

FENC

CA31447P1009

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:05:21 2024-03-28 am EDT 5-day change 1st Jan Change
11.25 USD +1.49% Intraday chart for Fennec Pharmaceuticals Inc. +1.26% -0.09%

Business Summary

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company, which is focused on its product candidate PEDMARK. The Company sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Number of employees: 36

Sales per Business

CAD in Million2021Weight2022Weight Delta
Sodium Thiosulfate
100.0 %
0 nan % 2 100.0 % -

Sales per region

CAD in Million2021Weight2022Weight Delta
United States
100.0 %
0 nan % 2 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 48 09-07-06
Director of Finance/CFO 49 09-07-06
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer 64 14-04-24
Comptroller/Controller/Auditor 52 15-10-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 70 11-08-24
Chairman 67 14-04-24
Director of Finance/CFO 49 09-07-06
Chief Operating Officer 64 14-04-24
Director/Board Member 70 16-08-09
Chief Executive Officer 48 09-07-06
Director/Board Member 56 19-09-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,040,306 22,264,960 ( 82.34 %) 0 82.34 %

Shareholders

NameEquities%Valuation
Southpoint Capital Advisors LP
15.31 %
4,077,214 15.31 % 39 M $
Southpoint Capital Advisors LP
15.31 %
4,077,214 15.31 % 39 M $
Essetifin SpA
14.99 %
3,993,694 14.99 % 38 M $
2,502,181 9.394 % 24 M $
Sonic Fund II LP
9.038 %
2,407,357 9.038 % 23 M $
Sonic GP LLC
9.038 %
2,407,357 9.038 % 23 M $
Solas Capital Management LLC
5.176 %
1,378,513 5.176 % 13 M $
Solas Capital Management LLC
5.176 %
1,378,513 5.176 % 13 M $
Avoro Capital Advisor LLC
4.505 %
1,200,000 4.505 % 11 M $
Vanguard Fiduciary Trust Co.
4.280 %
1,140,063 4.280 % 11 M $

Company contact information

Fennec Pharmaceuticals, Inc.

Research Triangle Park 68 T.W. Alexander Drive

27709, Durham

+919 636 4530

http://www.fennecpharma.com
address Fennec Pharmaceuticals Inc.(FENC)